Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
BIOA
BIOA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BIOA News
BioArctic AB Issues 78,000 Class B Shares Under Stock Option Program
Feb 27 2026
Newsfilter
Wall Street Analysts Adjust Ratings
Feb 25 2026
Benzinga
BioAge Labs to Present at Oppenheimer Healthcare Conference
Feb 19 2026
Newsfilter
Wall Street Analysts Adjust Ratings
Feb 18 2026
Benzinga
BioArctic to Release Q4 2025 Report on February 18, 2026
Feb 11 2026
Newsfilter
Leqembi Receives Priority Review in China
Feb 09 2026
PRnewswire
Leqembi Receives Priority Review in China
Feb 09 2026
PRnewswire
Leqembi Receives Priority Review in China
Feb 09 2026
Newsfilter
BioArctic's Leqembi Sales Surge in Q4 2025
Feb 06 2026
Newsfilter
BioArctic and Eisai Submit New Drug Application for Lecanemab
Jan 26 2026
Newsfilter
BioAge Labs (BIOA) Prices Upsized Public Offering at $19.50, Targeting $115M
Jan 22 2026
seekingalpha
BioAge Labs Prices Upsized Offering of 5.9 Million Shares at $19.50, Raising $115 Million
Jan 22 2026
Newsfilter
Netflix Reports Q4 Results, Q1 Guidance Misses Estimates
Jan 21 2026
Benzinga
BioAge Labs (BIOA) Proposes $75 Million Public Offering, Expands BGE-102 into Ophthalmology
Jan 21 2026
NASDAQ.COM
BioAge Labs (BIOA) Proposes $75M Public Offering of Common Stock
Jan 20 2026
seekingalpha
BioAge Launches BGE-102 Targeting Diabetic Macular Edema with Promising Clinical Data
Jan 20 2026
Newsfilter
Show More News
